XERS
Xeris Biopharma Holdings, Inc.
Set alert
10.71 USD -0.04 -0.37%
10.52 Day range 10.88
5.25 52-week range 11.42
- YTD
- +36.43%
- 1 year
- +10.30%
- Open
- 10.81
- Prev close
- 10.75
- Mkt cap
- 1.95B
- Vol
- 1.55M
- Avg vol
- 2.35M
- EPS
- -0.10
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.52
- High
- 10.88
- Forward P/E
- 54.46
- Beta
- 0.84
- Short ratio
- 2.46
- Inst. own
- 60.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 9.27
- 200-d avg
- 7.48
- 1y target
- 12.86
Key statistics
- Market cap
- 1.95B
- Enterprise value
- 2.13B
- Trailing P/E
- 0.00
- Forward P/E
- 54.46
- PEG ratio
- 0.00
- Price / sales
- 5.82
- Price / book
- 0.00
- EPS (TTM)
- -0.10
- Beta
- 0.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -5.12%
- Revenue (TTM)
- 335.41M
- Revenue growth
- 28.70%
- Free cash flow
- 52.45M
- Total cash
- 121.75M
- Total debt
- 289.44M
- Return on equity
- 0.00%
- Shares outstanding
- 182.32M
- Short % of float
- 4.55%
- 50-day average
- 9.27
- 200-day average
- 7.48
Analyst view
Consensus: none
Price target (mean) 12.86 +20.0% upside
Now 10.71
- Target (low)
- 8.00
- Target (mean)
- 12.86
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy1
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.02667.
Financials — quick view
XERS Revenue — quarterly 92.10M
XERS Net income — quarterly -31.10M
XERS EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.03167 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.01214 | -0.18 | -0.19 | -1,582.70% |
| May 7, 2026 | Mar 31, 2026 | -0.00274 | 0.01 | +0.01 | +464.96% |
| Mar 2, 2026 | Dec 31, 2025 | 0.03 | 0.06 | +0.03 | +100.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.01 | 0.0035 | -0.01 | -65.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.03 | -0.01 | +0.02 | +66.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays | main | Overweight | Overweight |
| Sep 10, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 20, 2026 | Barclays | main | Overweight | Overweight |
| Mar 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 9, 2025 | Barclays | init | — | Overweight |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- xerispharma.com
News
- Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100
- Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
- Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
- Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison
- Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
- Xeris Biopharma Files Patent Infringement Lawsuits Related To Its KEYEVIS Product In U.S. District Court In New Jersey
- Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
- Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14
- Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call
- Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT)
Your note
Sign in to keep a note on XERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Stock Award(Grant) | Jun 3, 2026 | 150,693 |
| HECHT BETH P | Officer | Sale | Aug 31, 2026 | 1,127,800 |
| JOHNSON JOHN H. | Director | Sale | Dec 18, 2025 | 698,083 |
| KONG GARHENG | Director | Stock Award(Grant) | Jun 3, 2026 | 238,337 |
| MCCULLOCH KEVIN | President | Sale | Sep 27, 2026 | 1,639,210 |
| NGUYEN ANH TU | Officer | Stock Award(Grant) | Jan 29, 2026 | 431,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.97% | 14,525,539 | 155.57M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.28% | 7,804,758 | 83.59M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.03% | 7,340,229 | 78.61M | Jun 29, 2026 |
| State Street Corporation | 2.64% | 4,821,566 | 51.64M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.59% | 4,718,183 | 50.53M | Jun 29, 2026 |
| Nuveen, LLC | 2.41% | 4,385,141 | 46.96M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.85% | 5,193,656 | 55.62M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 4,417,108 | 47.31M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.09% | 1,986,461 | 21.27M | Jun 29, 2026 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 1.07% | 1,951,890 | 20.90M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 1,868,647 | 20.01M | Jul 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.88% | 1,595,993 | 17.09M | Sep 29, 2026 |